Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease

D Capodanno, DL Bhatt, JW Eikelboom… - Nature Reviews …, 2020 - nature.com
Advances in antiplatelet therapies for patients with cardiovascular disease have improved
patient outcomes over time, but the challenge of balancing the risks of ischaemia and …

Antithrombotic therapy in diabetes: which, when, and for how long?

RA Ajjan, N Kietsiriroje, L Badimon… - European Heart …, 2021 - academic.oup.com
Cardiovascular disease remains the main cause of mortality in individuals with diabetes
mellitus (DM) and also results in significant morbidity. Premature and more aggressive …

[HTML][HTML] Thrombo-inflammation in cardiovascular disease: an expert consensus document from the Third Maastricht Consensus Conference on Thrombosis

E d'Alessandro, C Becker, W Bergmeier… - Thrombosis and …, 2020 - thieme-connect.com
Thrombo-inflammation describes the complex interplay between blood coagulation and
inflammation that plays a critical role in cardiovascular diseases. The third Maastricht …

[HTML][HTML] Dual pathway inhibition for vascular protection in patients with atherosclerotic disease: rationale and review of the evidence

JI Weitz, DJ Angiolillo, T Geisler… - Thrombosis and …, 2020 - thieme-connect.com
Despite advances in secondary prevention strategies in patients with cardiovascular
disease, the residual risk of recurrent atherothrombotic events remains high. Dual …

[HTML][HTML] Eligibility to intensified antithrombotic regimens for secondary prevention in patients who underwent percutaneous coronary intervention

A Greco, S Scilletta, DC Faro, F Agnello… - The American Journal of …, 2023 - Elsevier
Single antiplatelet therapy (SAPT) and intensified antithrombotic regimens (prolonged dual
antiplatelet therapy [DAPT] or dual pathway inhibition [DPI]) are recommended for …

Dual antithrombotic treatment in chronic coronary syndrome: European Society of Cardiology criteria vs. CHADS-P2A2RC score

M Würtz, KKW Olesen, MB Mortensen… - European Heart …, 2022 - academic.oup.com
Abstract Aims According to the 2019 European Society of Cardiology (ESC) guidelines on
chronic coronary syndromes (CCS), adding a P2Y12 inhibitor or rivaroxaban to aspirin …

Antithrombotic strategy in secondary prevention for high-risk patients with previous acute coronary syndrome: overlap between the PEGASUS eligibility and the …

M Millesimo, E Elia, G Marengo, O De Filippo… - American Journal of …, 2023 - Springer
Background Patients with previous acute coronary syndrome (ACS) are at high risk of
recurrent adverse cardiovascular events. Recently, prolonged dual antiplatelet therapy …

[HTML][HTML] Antithrombotic therapy in myocardial infarction: historic perils and current challenges—a 70-year journey

H Fernando, JD McFadyen… - Thrombosis and …, 2020 - thieme-connect.com
There have been numerous and intriguing advancements in antithrombotic therapy for
myocardial infarction since it was described in the earliest issues of Thrombosis and …

Patients with acute and chronic coronary syndromes have elevated long-term thrombin generation

C Yip, A Seneviratna, SH Tan, T Khaing… - Journal of Thrombosis …, 2020 - Springer
Coronary artery disease is a leading cause of morbidity and mortality worldwide. Despite
significant advances in revascularization strategies and antiplatelet therapy with aspirin …

Role of oral anticoagulant therapy for secondary prevention in patients with stable atherothrombotic disease manifestations

SW Cho, F Franchi… - Therapeutic Advances in …, 2019 - journals.sagepub.com
Coronary artery disease and peripheral arterial disease are strong predictors of risk for a
future ischemic event. Despite the utilization of effective secondary prevention strategies, the …